Randomized comparison of novel biodegradable polymer and durable polymer‐coated cobalt‐chromium sirolimus‐eluting stents: Three‐Year Outcomes of the I‐LOVE‐IT 2 Trial

Randomized comparison of novel biodegradable polymer and durable polymer‐coated... INTRODUCTIONNewer generation drug‐eluting stents (DES) have been developed. These stents feature thinner struts and biocompatible or biodegradable polymers that release eluted drug at lower dosages, resulting in a remarkable reduction in the risk of death, stent thrombosis (ST), or myocardial infarction (MI), as well as a lower risk of repeat revascularization . The biodegradable‐polymer sirolimus‐eluting stent (BP‐SES) (Tivoli, Essen Technology, Beijing, China) represents a further iteration of DES technology by combining a biodegradable polymer with cobalt–chromium (CoCr) platform. In the prior reported one‐year result of I‐LOVE‐IT 2 (Evaluate Safety and Effectiveness of the Tivoli DES and the Firebird DES for Treatment of Coronary Revascularization) trial, the BP‐SES was noninferior to the durable‐polymer sirolimus‐eluting stent (DP‐SES) (Firebird2, Microport Medical, Shanghai, China) in the primary composite safety and efficacy endpoint of target‐lesion failure (TLF) at 12 months . Nevertheless, long‐term data comparing the BP‐DES versus the DP‐DES are scarce. The purpose of this study was to report the long‐term clinical outcomes of patients included in the I‐LOVE‐IT 2 trial over a 3‐year follow‐up period.MATERIALS AND METHODSStudy Design and PatientsThe I‐LOVE‐IT 2 trial (NCT01681381) was a prospective, multicenter, randomized, assessor‐blinded, noninferiority study comparing the BP‐SES with the DP‐SES. Between October 2012 and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Catheterization and Cardiovascular Interventions Wiley

Randomized comparison of novel biodegradable polymer and durable polymer‐coated cobalt‐chromium sirolimus‐eluting stents: Three‐Year Outcomes of the I‐LOVE‐IT 2 Trial

Loading next page...
 
/lp/wiley/randomized-comparison-of-novel-biodegradable-polymer-and-durable-uJl9EX2bY8
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
1522-1946
eISSN
1522-726X
D.O.I.
10.1002/ccd.27465
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONNewer generation drug‐eluting stents (DES) have been developed. These stents feature thinner struts and biocompatible or biodegradable polymers that release eluted drug at lower dosages, resulting in a remarkable reduction in the risk of death, stent thrombosis (ST), or myocardial infarction (MI), as well as a lower risk of repeat revascularization . The biodegradable‐polymer sirolimus‐eluting stent (BP‐SES) (Tivoli, Essen Technology, Beijing, China) represents a further iteration of DES technology by combining a biodegradable polymer with cobalt–chromium (CoCr) platform. In the prior reported one‐year result of I‐LOVE‐IT 2 (Evaluate Safety and Effectiveness of the Tivoli DES and the Firebird DES for Treatment of Coronary Revascularization) trial, the BP‐SES was noninferior to the durable‐polymer sirolimus‐eluting stent (DP‐SES) (Firebird2, Microport Medical, Shanghai, China) in the primary composite safety and efficacy endpoint of target‐lesion failure (TLF) at 12 months . Nevertheless, long‐term data comparing the BP‐DES versus the DP‐DES are scarce. The purpose of this study was to report the long‐term clinical outcomes of patients included in the I‐LOVE‐IT 2 trial over a 3‐year follow‐up period.MATERIALS AND METHODSStudy Design and PatientsThe I‐LOVE‐IT 2 trial (NCT01681381) was a prospective, multicenter, randomized, assessor‐blinded, noninferiority study comparing the BP‐SES with the DP‐SES. Between October 2012 and

Journal

Catheterization and Cardiovascular InterventionsWiley

Published: Jan 15, 2018

Keywords: ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off